Please login to the form below
Remestemcel-L
This page shows the latest Remestemcel-L news and features for those working in and with pharma, biotech and healthcare.
Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study
Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress. ... Remestemcel-L was being studied in ventilator-dependent COVID-19 patients with moderate-to-severe acute respiratory distress (ARDS).
Latest news
-
Mesoblast expands compassionate use COVID-19 programme
The drug, an allogeneic mesenchymal stem cell (MSC) product candidate dubbed remestemcel-L, will now be available for children between the ages of two months and 15 years old infected with ... Remestemcel-L is comprised of culture-expanded mesenchymal
Mesoblast expands compassionate use COVID-19 programme
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Midweight-Senior Creative
-
Competitive Salary Offered
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- CONGREGO™ IS NOW MULTI-PLATFORM
- Onyx Health Marks Record Growth with Six New Appointments
- FDA expands use of COVID-19 antibody cocktail
- New European supply deals show Pfizer and Moderna have increased COVID-19 vaccine prices
- Ipsen’s spending spree bolsters neurology pipeline
- AMICULUM® launches Cence, a new specialist publications agency
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- Onyx Health Launch Creative Studio After Record Year
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
